Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

• I. García-Escobar ^[1] ; C. Beato-Zambrano ^[2] ; J. Muñoz Langa ^[3] ; E. Brozos Vázquez ^[4] ; B. Obispo Portero ^[5] ; D. Gutiérrez-Abad ^[6] ; A. J. Muñoz Martín ^[7]
  1. [1] Hospital General de Ciudad Real

     Hospital General de Ciudad Real

     Ciudad Real, España

     
  2. [2] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  3. [3] Hospital Universitario La Fe

     Hospital Universitario La Fe

     Valencia, España

     
  4. [4] Complexo Hospitalario Universitario de Santiago

     Complexo Hospitalario Universitario de Santiago

     Santiago de Compostela, España

     
  5. [5] Hospital Infanta Leonor

     Hospital Infanta Leonor

     Madrid, España

     
  6. [6] Hospital de Fuenlabrada

     Hospital de Fuenlabrada

     Fuenlabrada, España

     
  7. [7] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 9 (September 2018), 2018, págs. 1097-1108
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The association between venous thromboembolism (VTE) and cancer has been recognized for more than 100 years. Numerous studies have been performed to investigate strategies to decrease VTE incidence and to establish whether treating VTE impacts cancer progression and overall survival. Accordingly, it is important to understand the role of the hemostatic system in tumorigenesis and progression, as there is abundant evidence associating it with cell survival and proliferation, tumor angiogenesis, invasion, and dissemination, and metastasis formation. In attempts to further the scientific evidence, several studies examine survival benefits in cancer patients treated with anticoagulant therapy, specifically treatment with vitamin K antagonists, unfractionated heparin, and low-molecular-weight heparin. Several studies and meta-analyses have been conducted with a special focus on brain tumors. However, no definitive conclusions have been obtained, and more well-designed clinical trials are needed.